All In Biotech

Free tool

FAERS Monitor: Cyramza

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 125477 or its brand name (Cyramza, Ramucirumab). Reports on generic versions are filed under their own applications.

Reports

6,320

Serious

5,943

94% of reports

Hospitalization

2,396

Death reported

1,693

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • malignant neoplasm progression817
  • death614
  • interstitial lung disease301
  • neutropenia268
  • febrile neutropenia265
  • decreased appetite234
  • diarrhoea229
  • off label use218
  • nausea209
  • disease progression204
  • fatigue203
  • hypertension194
  • pyrexia191
  • ascites181
  • neutrophil count decreased179

Reports by year received

View as table
YearReports
20115
201217
201313
2014131
2015405
2016471
2017621
2018687
2019630
2020519
2021628
2022533
2023502
2024474
2025386
2026298

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,047,839 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
malignant neoplasm progressionSignal81726.825.120,167
interstitial lung diseaseSignal30120.818.65,635
ascitesSignal18120.617.83,342
neutrophil count decreasedSignal17914.712.72,262
febrile neutropeniaSignal26513.311.93,011
neutropeniaSignal2686.65.81,266
disease progressionSignal2045.75.0798
decreased appetiteSignal2343.43.0388
hypertensionSignal1943.12.7268
deathSignal6142.42.2507
pyrexia1911.81.673
diarrhoea2291.21.06
nausea2090.90.84
fatigue2030.90.84
off label use2180.80.78

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.